<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046292</url>
  </required_header>
  <id_info>
    <org_study_id>GBE LI 1370</org_study_id>
    <nct_id>NCT01046292</nct_id>
  </id_info>
  <brief_title>Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI</brief_title>
  <official_title>Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI: a Randomized, Double-blind, Placebo-controlled Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effects of Ginkgo Biloba Extract (GBE) in executive
      function-impaired Mild Cognitive Impairment (MCI) patients by assessing gait while walking
      alone as well as under differing dual-task conditions.

      The primary endpoint in the evaluation of GBE efficacy is gait speed. The secondary endpoint
      is cycle time variability under dual-task conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gait speed</measure>
    <time_frame>baseline, 3, 6, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cycle time variability</measure>
    <time_frame>baseline, 3, 6, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Ginkgo biloba</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo biloba</intervention_name>
    <description>The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.</description>
    <arm_group_label>Ginkgo biloba</arm_group_label>
    <arm_group_label>Placebo control</arm_group_label>
    <other_name>Symfona® forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50-85 years

          -  Swiss German or German speaker

          -  Completed elementary school

          -  Impaired executive function (gait speed reduction ≥ 10% under dual-task as compared to
             normal walking)

          -  No dementia according to International Classifications of Diseases (ICD)-10 and
             Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV.

          -  Cognitive decline (self/informant report or objective task)

          -  Preserved basic activities of daily living and minimal impairment in complex
             instrumental functions

          -  Written informed consent and nihil obstat

        Exclusion Criteria:

          -  Current drug treatment with Warfarin-like drugs (Coumarins or Clopidogrel), however,
             acetylsalicylic acid 100mg and 300mg is permitted

          -  Current intake of GBE or during the last 6 months

          -  Known hypersensitivity to GBE or its constituents

          -  Regular intake of antipsychotic, anxiolytic or sedative drugs(allowed if clinically
             stable for at least the past 3 months while under treatment)

          -  Concomitant gait-relevant disorders: severe cardio/pulmonary/cerebron -vascular
             disorders, bleeding diathesis, polyneuropathy and severe orthopedic disorders, organic
             cerebral disease epilepsy, low vision

          -  Severe medical conditions (e.g. chronic renal insufficiency, severe hepatic
             disorders,cardio-vascular disease, uncontrolled hypertension, peptic ulcer, malignoma)

          -  Participation in another clinical intervention study within the last 2 months

          -  Use of walking aid

          -  Normal walking speed is &lt; 100cm/s
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto W Kressig, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basel University Hospital, Basel Mobility Center</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gait, Ginkgo biloba, mild cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

